SGLT2 Inhibitors Show Superior Kidney Protection Over GLP-1RAs in Type 2 Diabetes
Feb 13, 2026
Real-world study finds SGLT2 inhibitors reduce chronic kidney disease and acute kidney injury risk more effectively than GLP-1 receptor agonists in patients with type 2 diabetes, with greatest benefits in those without preexisting kidney disease.